Skip to content

Cannabis: all studies

Page 151 of 294: studies 1,501 to 1,510 of 2,937, newest first. Back to the cannabis overview

Research

Adolescent Cannabis Use, Psychosis and Catechol-O-Methyltransferase Genotype in African Americans and Caucasians

Psychiatric Quarterly July 25, 2009 Joshua T. Kantrowitz, K. Nolan, Srijan Sen et al.

Cannabis has been reported as a likely risk factor for the development of psychosis, and a gene × environment interaction with the catechol-O-methyltransferase (COMT) gene has been proposed. Moreover, COMT has been separately linked to affective symptoms in psychosis. Despite a high rate of cannabis abuse and affective symptoms in African Americans, no studies exploring a relationship between...

Neuroimaging in cannabis use: a systematic review of the literature

Psychological Medicine July 23, 2009 Rocío Martín‐Santos, Ana B. Fagundo, José Alexandre S. Crippa et al. 207 citations

BACKGROUND: We conducted a systematic review to assess the evidence for specific effects of cannabis on brain structure and function. The review focuses on the cognitive changes associated with acute and chronic use of the drug. METHOD: We reviewed literature reporting neuroimaging studies of chronic or acute cannabis use published up until January 2009. The search was conducted using Medline,...

DOI: 10.1017/s0033291709990729 (opens in new tab) Cannabidiol Positron emission tomography Resting State FMRI Functional neuroimaging +7

Cannabis and psychosis/schizophrenia: human studies

European Archives of Psychiatry and Clinical Neuroscience July 16, 2009 Deepak C. D’Souza, Richard A Sewell, Mohini Ranganathan

The association between cannabis use and psychosis has long been recognized. Recent advances in knowledge about cannabinoid receptor function have renewed interest in this association. Converging lines of evidence suggest that cannabinoids can produce a full range of transient schizophrenia-like positive, negative, and cognitive symptoms in some healthy individuals. Also clear is that in...

Reduced memory and attention performance in a population-based sample of young adults with a moderate lifetime use of cannabis, ecstasy and alcohol.

Journal of Psychopharmacology July 2009 F Indlekofer, M Piechatzek, M Daamen et al.

Regular use of illegal drugs is suspected to cause cognitive impairments. Two substances have received heightened attention: 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy') and delta-9-tetrahydrocannabinol (THC or 'cannabis'). Preclinical evidence, as well as human studies examining regular ecstasy consumers, indicated that ecstasy use may have negative effects on learning, verbal memory...

Cannabis and schizophrenia spectrum disorders: a review of clinical studies.

Indian Journal of Psychological Medicine July 1, 2009 Chaturaka Rodrigo, Senaka Rajapakse

Cannabis is the most widely used illegitimate substance in the world, and the number of users has increased by 10% over the last decade worldwide. Therefore, it is important to review the evidence on psychoactive properties of cannabis and its possible association with schizophrenia spectrum disorders (SSD). We searched MEDLINE with the key words cannabis and schizophrenia. The search was...

Impaired error awareness and anterior cingulate cortex hypoactivity in chronic cannabis users

Neuropsychopharmacology June 24, 2009 R. Hester, Liam Nestor, Hugh P Garavan

Drug abuse and other psychiatric conditions (eg, schizophrenia) have been associated with a diminished neural response to errors, particularly in the anterior cingulate cortex (ACC) thought critical to error processing. A diminished capacity for detecting errors has been linked to clinical symptoms including the loss of insight, delusions, and perseverative behavior. A total of 16 active...

Synthetic delta-9-tetrahydrocannabinol (dronabinol) can improve the symptoms of schizophrenia.

Journal of Clinical Psychopharmacology June 2009 Glenn Schwarcz, Basawaraj Karajgi, Richard McCarthy

We are reporting improvement of symptoms of schizophrenia in a small group of patients who received the cannabinoid agonist dronabinol (synthetic Delta-9-tetrahydrocannabinol). Before this report, cannabinoids had usually been associated with worsening of psychotic symptoms. In a heuristic, compassionate use study, we found that 4 of 6 treatment-refractory patients with severe chronic...

Acute cannabis use causes increased psychotomimetic experiences in individuals prone to psychosis

Psychological Medicine June 1, 2009 O. Mason, C. J. A. Morgan, S. K. Dhiman et al.

BackgroundEpidemiological evidence suggests a link between cannabis use and psychosis. A variety of factors have been proposed to mediate an individual's vulnerability to the harmful effects of the drug, one of which is their psychosis proneness. We hypothesized that highly psychosis-prone individuals would report more marked psychotic experiences under the acute influence of cannabis.MethodA...

The depressive phenotype induced in adult female rats by adolescent exposure to THC is associated with cognitive impairment and altered neuroplasticity in the prefrontal cortex.

Neurotoxicity Research May 2009 Tiziana Rubino, Natalia Realini, Daniela Braida et al.

We recently demonstrated that Delta(9)-tetrahydrocannabinol (THC) chronic administration in female adolescent rats induces alterations in the emotional circuit ending in depressive-like behavior in adulthood. Since cognitive dysfunction is a major component of depression, we assessed in these animals at adulthood different forms of memory. Adolescent female rats were treated with THC or its...

The influence of cannabis use expectancies on cannabis use and psychotic symptoms in psychosis

Drug and Alcohol Review May 1, 2009 Leanne M Hides, David J. Kavanagh, Sharon Dawe et al.

Abstract: Introduction and Aims. Little is known about motives or expectancies for cannabis use in psychotic populations, despite these cognitive factors being a central focus of the treatment for substance misuse in psychosis. This study examined the relationship between cannabis use expectancies, cannabis use and psychotic symptoms among cannabis using psychotic inpatients. A secondary aim...